Novo Nordisk is also looking to extend the indications for semaglutide even further, with trials on the go in metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer's disease.
While the back of the upper arm is a valid injection site, it can be difficult to reach and pinch the skin simultaneously when working alone
What no alternative on the list evaluates is the upstream genetic terrain that shapes how your body meets any of these compounds
At week 64, the active treatment group lost an average of 13.6% of their body weight, compared with 2.2% on placebo, a difference of 11.4 percentage points
In these studies, no major adverse events have been reported
That is a radically different outcome than the registration trials, and it demonstrates that the lean mass loss is not inevitable